✦ LIBER ✦

A phase II study of idarubicin in the treatment of measurable gastric cancer

✍ Scribed by Ronald Maccormick; Geralynn Hirsch; Sunil Gupta; Pat Shannon; Lorne Rotstein

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 165 KB
Volume: 67
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910615)67:12<2988::aid-cncr2820671209>3.0.co;2-b

No coin nor oath required. For personal study only.

✦ Synopsis

Idarubicin is one of the new anthracycline analogues. It has a higher therapeutic index than either doxorubicin or daunorubicin in a variety of murine leukemias and solid tumors. The authors performed a multicenter Phase II trial of idarubicin in patients with advanced gastric cancer. Seventeen patients with measurable metastatic disease were entered into the trial and treated with idarubicin at a starting dose of 15 mg/m2. This dose was escalated or reduced according to toxicity. There were no documented responses. The dose-limiting toxicity was myelosuppression. These data did not compared favourably with the data on doxorubicin in the treatment of gastric carcinoma. A conclusion could not be reached on whether idarubicin has minimal activity in the treatment of gastric carcinoma.

📜 SIMILAR VOLUMES

Treatment of myelodysplastic syndromes w

Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I–II study

✍ Bernard R. Greenberg; Ralph D. Reynolds; Carolyn B. Charron; Kathleen M. Squilla 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 375 KB 👁 1 views

A phase ii study of the combination of e

A phase ii study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer

✍ Thomas E. Elliott; Charles G. Moertel; Harry S. Wieand; Richard G. Hahn; James B 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 1 views

Forty-eight patients with advanced gastric cancer and measurable areas of malignant disease were treated with etoposide (130 mg/mz/day X 3 days) plus cisplatin (45 mg/mzday on days 2 and 3). Both drugs were given by constant intravenous infusion and repeated every 4 weeks. Common toxic reactions inc

Phase II study of 5-fluorouracil and fol

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study

✍ Giuseppe Colucci 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our

Phase II study of 5-fluorouracil and fol

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A southwest oncology group study

✍ Jeffrey L. Berenberg; Catherine Tangen; John S. Macdonald; Laura F. Hutchins; Ro 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Phase II study of flutamide in the treat

Phase II study of flutamide in the treatment of hepatocellular carcinoma

✍ Yee Chao; Wing-Kai Chan; Yi-Shin Huang; Ho-Chung Teng; Sun-Sang Wang; Wing-Yiu L 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB 👁 1 views

## BACKGROUND. Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase I1 study was designed to investigate the clinical activity and toxicity of flutamide in the treatment of patients with advanced HCC. METHODS. Thirty

Modern trends in the treatment of gastri

Modern trends in the treatment of gastric cancer

✍ Kaichi Isono 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views